Skip to main content

Peer Review reports

From: Inhibiting PRMT5 induces DNA damage and increases anti-proliferative activity of Niraparib, a PARP inhibitor, in models of breast and ovarian cancer

Original Submission
12 Apr 2023 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
Resubmission - Version 3
Submitted Manuscript version 3
Resubmission - Version 4
Submitted Manuscript version 4
8 Jun 2023 Reviewed Reviewer Report
13 Jun 2023 Reviewed Reviewer Report
16 Jun 2023 Reviewed Reviewer Report
28 Jul 2023 Author responded Author comments - Andy Fedoriw
Resubmission - Version 5
28 Jul 2023 Submitted Manuscript version 5
1 Aug 2023 Author responded Author comments - Andy Fedoriw
Resubmission - Version 6
1 Aug 2023 Submitted Manuscript version 6
2 Aug 2023 Reviewed Reviewer Report
2 Aug 2023 Reviewed Reviewer Report
2 Aug 2023 Reviewed Reviewer Report
Resubmission - Version 7
Submitted Manuscript version 7
Publishing
5 Aug 2023 Editorially accepted
18 Aug 2023 Article published 10.1186/s12885-023-11260-z

You can find further information about peer review here.

Back to article page